You are here
Company Discovers New Antibiotic Compound
The compound, AQP-182, has demonstrated bactericidal potency against multidrug-resistant Staphylococcus aureus (MDRSA), multidrug-resistant Streptococcus pneumoniae (MDRSP), Clostridium difficile, and Enteroccocus faecalis—common causes of death in patients in hospital care units.
AQP-182 is one of the novel drug-like molecules identified by Aquapharm from its collection of more than 10,000 marine microorganisms. The company has identified 16 molecules of interest. AQP-182 is the most advanced of these molecules because of its activity against multi–drug-resistant gram-positive bacteria, with in vitro minimum inhibitory concentrations against MDRSA below 0.016 mcg/mL.
Aquapharm expects to initiate a phase I clinical study of AQP-182 in the second half of 2013.
For more information, visit the Aquapharm Biodiscovery Web site.